Who is eligible for clinical trial NCT05609578?

Participants must meet protocol criteria for Advanced NSCLC. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT05609578 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-06-18

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation (NCT05609578)

A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Mirati Therapeutics Inc.

🩺 Plain-English Summary (8th-Grade Level)

Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation

Who can join: Review the eligibility criteria below.

Location: Local Institution - 017-936C — Fountain Valley, California

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (94 Sites)

Showing the first 25 of 94 sites.

Local Institution - 017-936C — Fountain Valley, California
Local Institution - 017-936 — Fountain Valley, California
Local Institution - 017-851 — Fullerton, California
Local Institution - 017-540 — San Francisco, California
Local Institution - 017-872-I — Aurora, Colorado
Local Institution - 017-872-G — Boulder, Colorado
Local Institution - 017-872-D — Colorado Springs, Colorado
Local Institution - 017-872-J — Colorado Springs, Colorado
Local Institution - 017-872-B — Denver, Colorado
Local Institution - 017-872-F — Denver, Colorado
Local Institution - 017-872-A — Lakewood, Colorado
Local Institution - 017-872-C — Littleton, Colorado
Local Institution - 017-872 — Lone Tree, Colorado
Local Institution - 017-872-E — Pueblo, Colorado
Local Institution - 017-872-H — Thornton, Colorado
Local Institution - 017-829 — Jacksonville, Florida
Local Institution - 017-898 — Lakeland, Florida
Local Institution - 017-972 — Chicago, Illinois
Local Institution - 017-820J — Fairway, Kansas
Local Institution - 017-820A — Kansas City, Kansas
Local Institution - 017-820B — Kansas City, Kansas
Local Institution - 017-820C — Kansas City, Kansas
Local Institution - 017-820H — Kansas City, Kansas
Local Institution - 017-820I — Overland Park, Kansas
Local Institution - 017-820 — Westwood, Kansas

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced NSCLC

Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC — La Jolla, California

Explore by condition: All Advanced NSCLC clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗